SBIO commences HRPC Phase 2 clinical trial

SBIO claims that SB939 is designed to be a best-in-class HDAC inhibitor, and has demonstrated the potential to bring additional therapeutic benefits due to its high potency, superior oral availability and good tolerability.

The primary objective of the trial is to determine the compound’s efficacy, which will be measured by the prostate-specific antigen (PSA) responses and progression free survival, in HRPC patients who received up to one prior chemotherapy regimen.

Where as, the secondary objectives include the determination of objective response, the response duration in patients with measurable disease at baseline, and the tolerability and toxicity of SB939 in the study’s patient population as well as investigation of biomarkers in circulating tumour cells.

SBIO CEO Jan-Anders Karlsson said that advancing into Phase 2 clinical studies with HDAC inhibitor is a key milestone for SBIO.

“There is a significant unmet medical need for a viable treatment of HRPC and entering into Phase 2 trials with SB939 shows our full commitment in providing patients and physicians with an effective and safe option to treat this disease,” Karlsson said.